Industry News
Excerpt from the Press Release: Neutralizing antibodies develop within two weeks of a SARS-CoV-2 infection, but their durability and intensity can vary by individual, prompting concerns about the prospects of long-lasting immunity and efficacy of COVID-19 vaccines. In a PLOS ONE paper, published online February 11, 2021, researchers at University of California San Diego School…
Read More
Excerpt from the Article: CT, MRI, and ultrasound images reveal the myriad of ways the virus prompts the body to attack itself – with this knowledge, radiologists can better contribute to treatment planning. Not only does COVID-19 attack the body, but radiology images show that the virus can actually make the body attack itself. For…
Read More
Excerpt from the Press Release: Scientists at Sanford Burnham Prebys Medical Discovery Institute have designed a next-generation drug, called SBP-7455, which holds promise as a treatment for triple-negative breast cancer—an aggressive cancer with limited treatment options. The drug blocks a cellular recycling process called autophagy, which cancer cells hijack as a way to resist treatment.…
Read More
Excerpt from the Press Release: BOSTON, Feb. 08, 2021 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced the publication of new data highlighting the highly potent in vitro antiviral activity of AT-527 against SARS-CoV-2. AT-527 is an orally administered, direct-acting antiviral developmental agent derived from Atea’s purine nucleotide…
Read More
Excerpt from the Article: February 11, 2021 | Messenger RNA (mRNA) vaccines were the focus of a symposium on COVID-19 vaccines held during last week’s COVID-19 and Cancer virtual meeting of the American Association for Cancer Research. To date, only two vaccines have received Emergency Use Authorization by the U.S. Food and Drug Administration and…
Read More
Excerpt from the announcement: Take your first steps toward entrepreneurship with Building a Biotech Venture, a new program for regenerative medicine-focused trainees in labs at the University of Toronto (U of T) and its affiliated hospitals, offered in partnership with the Health Innovation Hub, a campus-linked accelerator at the Temerty Faculty of Medicine at U of T. In the H2i 10…
Read More
Excerpt from the Article: Verily is teaming up with Johnson & Johnson’s Janssen division to observe the body’s earliest immune responses to a coronavir12us infection, with people participating in the research from within their own homes. The study will be launched through Verily’s Project Baseline testing program and aims to collect biological information and real-world…
Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–DexCom, Inc. (Nasdaq: DXCM), the global leader in continuous glucose monitoring for people with diabetes, today announced the launch of Dexcom Ventures. The inaugural fund will seek to identify and invest in opportunities to supplement growth in the core business and advance the development of adjacent technologies for…
Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Trefoil Therapeutics today announced it has begun a Phase 2 clinical trial of its engineered Fibroblast Growth Factor-1, TTHX1114, to evaluate its safety and efficacy as a regenerative treatment for patients with Fuchs Endothelial Corneal Dystrophy (FECD). The “STORM” study, the second clinical trial of TTHX1114, is designed…
Read More
Excerpt from the Article: The Hospital of the University of Pennsylvania offers guidance – BI-RADS scoring and follow-up recommendations – for unilateral axillary lymphadenopathies seen on breast MRI in women who have received the vaccine. The baseline breast MRI of a 48-year-old woman who has the BRCA1 mutation, as well as a strong family history…
Read More